Literature DB >> 9886404

Structural features of autoreactive TCR that determine the degree of degeneracy in peptide recognition.

S Hausmann1, M Martin, L Gauthier, K W Wucherpfennig.   

Abstract

Structural aspects of human TCRs that allow the activation of autoreactive T cells by diverse microbial peptides were examined using two human myelin basic protein (MBP)-specific T cell clones. The TCR sequences of these clones differed only in the N region of TCR-alpha and -beta since the clones had the same Valpha-Jalpha and Vbeta-Jbeta rearrangements. The two clones had a similar fine specificity for the MBP peptide, except for the P5 position of the peptide (lysine). In the crystal structure of the HLA-DR2/MBP peptide complex, P5 lysine is a prominent, solvent-exposed residue in the center of the DR2/MBP peptide surface. Five microbial peptides with conservative or nonconservative changes at the P5 position (lysine to arginine, serine, or proline) activated one of these clones. In contrast, the other clone was activated only by three of these peptides which had a conservative lysine to arginine change at P5. The degree of specificity/degeneracy in recognition of the P5 side chain was the key difference between these TCRs since the Escherichia coli/Haemophilus influenzae peptide stimulated both clones when the P5 position was substituted from serine to arginine. These results demonstrate that the complementarity-determining region 3 loops contribute to the degree of degeneracy in peptide recognition by human MBP-specific TCRs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886404

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Infection, mimics, and autoimmune disease.

Authors:  N R Rose
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Mechanisms for the induction of autoimmunity by infectious agents.

Authors:  K W Wucherpfennig
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 3.  Unusual features of self-peptide/MHC binding by autoimmune T cell receptors.

Authors:  Melissa J Nicholson; Michael Hahn; Kai W Wucherpfennig
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

4.  Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display.

Authors:  Fei Wen; Dhruv K Sethi; Kai W Wucherpfennig; Huimin Zhao
Journal:  Protein Eng Des Sel       Date:  2011-07-13       Impact factor: 1.650

Review 5.  TCR recognition of peptide/MHC class II complexes and superantigens.

Authors:  Eric J Sundberg; Lu Deng; Roy A Mariuzza
Journal:  Semin Immunol       Date:  2007-06-07       Impact factor: 11.130

Review 6.  Cross-immune tolerance: conception and its potential significance on transplantation tolerance.

Authors:  Yong Zhao; Xianchang Li
Journal:  Cell Mol Immunol       Date:  2009-12-23       Impact factor: 11.530

7.  Positioning of autoimmune TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex.

Authors:  Zenichiro Kato; Joel N H Stern; Hironori K Nakamura; Kazuo Kuwata; Naomi Kondo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-29       Impact factor: 11.205

8.  An alternative conformation of the T-cell receptor alpha constant region.

Authors:  Gijs I van Boxel; Samantha Holmes; Lars Fugger; E Yvonne Jones
Journal:  J Mol Biol       Date:  2010-05-31       Impact factor: 5.469

9.  Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis.

Authors:  Maria Cristina De Rosa; Bruno Giardina; Caterina Bianchi; Cristiana Carelli Alinovi; Davide Pirolli; Gianfranco Ferraccioli; Maria De Santis; Gabriele Di Sante; Francesco Ria
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

Review 10.  Structural alterations in peptide-MHC recognition by self-reactive T cell receptors.

Authors:  Kai W Wucherpfennig; Melissa J Call; Lu Deng; Roy Mariuzza
Journal:  Curr Opin Immunol       Date:  2009-08-19       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.